Shares of Moderna Inc. MRNA,
they gained 2.2% in pre-sale trading on Thursday after the company reported half a million dollars in sales of their COVID-19 vaccine in the fourth quarter of last year. The company had a loss of $ 272,000, or 69 cents per share, in the fourth quarter of 2020, compared to a loss of $ 123,000, or 37 cents per share, in the same quarter a year ago. The FactSet consensus was for a loss of 34 cents. It had revenues of $ 570.7 million in the fourth quarter of last year, up from $ 14.1 million in the same quarter ago, as its COVID-19 vaccine began to be distributed in several countries across the country. world, including the U.S. The FactSet consensus was $ 279 million in revenue for the quarter. Vaccination is the first authorized product in the company’s history. Moderna said it expects to produce at least 700 million doses of its vaccine in 2021, up from a previous low-range estimate of 600 million, with a new target of 1.4 billion doses in 2022. company that they have completed registration in anticipation of a clinical trial testing the COVID-19 vaccine in teens, and a Phase 2 trial for children between 6 months and 11 years of age in the ” near term. “Moderna stock has accumulated 509.4% over the last 12 months, and the S&P 500 SPX more broadly,
up 21.7%.